Combination targeted therapy for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether adding a drug called everolimus to a targeted therapy called trastuzumab rezetecan is more effective than the targeted therapy alone for people with a specific type of triple-negative breast cancer (called LAR subtype) that has spread or come back. The combination aims to improve treatment response and potentially help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman between 18 and 70 years old
- Have triple-negative breast cancer that has spread or come back and cannot be removed by surgery
- Have already had up to 2 prior treatments for advanced disease
- Be generally well enough to care for yourself (ECOG performance status 0-1)
- Have at least one tumor that can be measured on a scan
- Have no brain metastases, and no prior treatment with an antibody-drug conjugate (such as T-DM1 or other targeted drug that carries chemotherapy)
- Have acceptable organ function (heart, liver, kidneys, blood counts) based on recent tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two targeted therapies for a specific type of triple-negative breast cancer. The goal is to see if adding a second drug improves the effectiveness of the first treatment in slowing the cancer's growth.
This trial tests a stronger post-surgery treatment to reduce the chance of breast cancer coming back in women with a certain type of triple-negative breast cancer (one that also has high androgen receptor activity). If you already had chemo before surgery but it didn't completely eliminate the cancer, this might be an option for you.
This study tests two treatments for advanced breast cancer that has stopped responding to a common class of drugs. It combines a targeted pill (famitinib) with an experimental antibody-drug treatment (SHR-A1811) to see if the combination works better than the antibody-drug alone.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
This trial tests an experimental drug called QLC5513, either by itself or combined with another drug (QL1706), for people with triple-negative breast cancer that has continued to grow despite prior treatment. The goal is to see if this new approach can shrink tumors or slow the cancer's progression, and it might be an option if standard treatments have stopped working.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.